clinical trial · NCT06390111
A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
Bladder CancerTa/T1CISnadofaragene firadenovec
brief summary
In this phase 4 trial (000439), subjects with NMIBC CIS (± high-grade Ta/T1) who have not responded to their first dose of nadofaragene firadenovec (commercial ADSTILADRIN received before trial entry) will be offered reinduction when entering the trial.
started
Jun 17, 2024
primary completion
Jul 31, 2026
completion
Jul 31, 2026
last updated
Nov 22, 2024
official title
A Phase 4, Multi-center, Open Label Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol